Drug intelligence / Profile preview

Oncolipin-IT Melanoma

Development stage: Preclinical
Lead developer: XEME Biopharma
Modality: Cytokines & Interferons → Recombinant Proteins and Enzymes, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics

Overview

Oncolipin-IT Melanoma is an investigational therapeutic developed by XEME Biopharma for the treatment of melanoma, a type of skin cancer. The drug is currently in preclinical development and is being explored for its potential use in neoplasms, specifically skin and subcutaneous tissue cancers. Detailed information about its mechanism of action, modality, or specific molecular targets has not been disclosed publicly as of June 2025[1]. There are no available data indicating whether it acts as an immunotherapy (such as checkpoint inhibitor or TIL therapy), targeted therapy, oncolytic virus therapy, or another modality.

Brand names: Oncolipin-IT Melanoma
Other names: Oncolipin-IT Melanoma

Targets

IL-2R (Interleukin-2/interleukin-15 receptor complex)

Beyond the preview

Go deeper on Oncolipin-IT Melanoma.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Oncolipin-IT Melanoma.

Explore the full profile